# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Jeff Jones reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and maintains $80 price tar...
B. Riley Securities analyst Kalpit Patel initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and an...
In a recent move signaling strategic financial planning, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that Dr...